【Heron Biotech】Application for Phase II Clinical Trial of B10 L-BPA Injection for Triple-Negative Breast Cancer
NQ Score
49/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Heron Biotech announced the submission of an IND application to the Taiwan TFDA for a Phase II clinical trial of B10 L-BPA injection for triple-negative breast cancer.
AI Analysis
Frequently Asked Questions
- Q: What is BNCT?
- A: Boron Neutron Capture Therapy.